The islet tissue, called Brockmann bodies, in certain teleost fish is anatomically distinct from the pancreatic exocrine tissue and can be easily identified macroscopically. Expensive islet isolation procedures, such as required when procuring islet tissue from mammalian pancreases, are unnecessary. Tilapia islets transplanted into diabetic athymic nude mice will produce long-term normoglycemia and mammalian-like glucose tolerance profiles. Encapsulated tilapia islets function well after transplantation into euthymic recipients. Additionally, tilapia are potentially ideal xenogeneic donors because of markedly lower donor production costs, minimal islet procurement costs, and possibly decreased xenozoonotic potential relative to mammalian donors. Tilapia islets appear to be appropriately glucose responsive with high insulin output, can be cryopreserved, and are much more resistant to hypoxia than mammalian islets. Because tilapia and human insulin differ by 17 amino acids, we have cloned, sequenced, and modified the tilapia insulin gene by site-directed mutagenesis resulting in a tilapia insulin gene that codes for "humanized" insulin while still maintaining all of the tilapia regulatory (noncoding) sequences. We have now produced small numbers of founder transgenic tilapia with incorporation of our humanized tilapia insulin gene construct, and we have shown transmission and expression of the transgene in the beta cells and serum of their F1 offspring. Our ultimate goal is to achieve homologous recombination and to breed for homozygosity for the hybrid insulin gene. Subsequent generations of transgenic tilapia will undergo a program of genomic optimization selecting for growth, survival, and fecundity as well as stability of the transgene. Islets from the resulting transgenic fish, after extensive characterization, could be harvested, encapsulated, and then transplanted into diabetic patients.
INTRODUCTION
ment for IDDM if several obstacles could be overcome. First, islets comprise only 1% of the human pancreas; yields from human "islet isolation" procedures are ex-Insulin-dependent diabetes mellitus (IDDM) is a disease resulting in significant morbidity and mortality.
tremely variable and several human donor pancreases are often required to generate sufficient islets for a sin-Although the acute manifestations of IDDM can be controlled with daily insulin injections, most patients even-gle transplant. Second, islet allograft rejection has proven difficult to manage using conventional methods tually develop sequelae such as blindness, nephropathy, neuropathy, microangiopathy, and cardiovascular dis-and, unfortunately, the majority of islet allografts are quickly lost. Third, many standard and experimental im-ease (83) . Substantial evidence suggests that meticulous control of glycemia will prevent or minimize these se-munosuppressive agents are directly toxic to islets while other agents such as steroids are diabetogenic. Finally, quelae (12, 99) . Theoretically, islet transplantation could safely provide the needed level of meticulous control.
there are insufficient human donor pancreases available to treat the vast numbers of type I diabetic patients. Islet transplantation could become a feasible treat- 126 WRIGHT AND POHAJDAK Therefore, it seems likely that widespread implementa-sulin by endopeptidases; therefore, the genes for these tion of islet transplantation would require the developcleavage enzymes would also have to be inserted. To ment of clinical islet xenotransplantation (60,61,100, package all of this into a cell that will readily propagate 115). In response to this eventuality, many biomedical in culture is almost inconceivable. Therefore, investigacorporations are spending millions of dollars developing tors have attempted to modify cell lines composed of and patenting "bioartificial pancreas" technologies (i.e., neoplastic endocrine cells, which already possess the microencapsulation or macroencapsulation of islet tisability to secret and process hormones; some of these sue). The underlying concept behind these approaches is cell lines have functional and relevant endopeptidases that the islet tissue is protected from the immune system for cleaving prohormones to hormones. Unfortunately, by a membrane with "pore" sizes small enough to presuitable human insulinoma cell lines were not available. vent immunocytes and antibodies from damaging the Therefore, these investigators focused their efforts on graft yet large enough for insulin, oxygen, glucose, and transformed rodent beta cell lines such as RIN cells or nutrients to pass freely (59, (63) (64) (65) . A number of recent HIT cells. However, most of these beta cell lines proved reviews deal with encapsulation devices and, therefore, not to be particularly glucose responsive and those we will not cover these except as they specifically imthat were tended to lose this ability with the passage of pact upon the selection of islet donor sources. The retime (4). mainder of this article will deal with selection of suitable In the early and mid-1990s, Newgard's group donor species for clinical islet xenotransplantation using reported initially promising results with a murine bioartificial pancreas technologies.
ACTH-secreting pituitary cell line transfected with the GLUT-2 glucose transporter (41); this strategy resulted THE IDEAL ISLET in glucose-stimulated insulin secretion, but, because these cells have higher hexokinase I and lower glucoki-If one were to specifically design an islet for encapnase activities than beta cells, maximal insulin release sulation and transplantation, what would its characterisoccurred at subphysiologic concentrations of glucose. tics be? According to Dionne et al. (15) , "the ideal tissue has a high insulin output, is correctly regulated by glu-Although it is possible that this problem could be adcose and other secretogogues, has low metabolic dedressed by knocking out hexokinase by homologous remand, and is capable of functioning for extended periods combination, preliminary transplantation studies in nude without replacement. In addition, the cells must be prorats were not terribly promising in that graft-bearing rats curable in high yield at reasonable cost with protocol developed significant tumor loads, cachexia, a 10-fold meeting FDA standards." In addition to these features, increase in adrenal mass, and steroid-induced insulin rethe tissue should produce insulin that is similar (or idensistance; the latter findings were secondary to the contical) to human insulin. To facilitate the logistics of islet tinued production of ACTH by these pituitary-derived storage, quality control testing, shipping, and transplancells (4). Because it would probably be necessary to tation, the tissue should tolerate culture and cryopreserknock out ACTH production as well, this group then vation.
switched to rodent insulinoma cell lines, which they have now engineered to simultaneously express GLUT-BIOENGINEERING AN ARTIFICIAL 2, glucokinase, and human insulin genes; this resulted in BETA CELL a moderate degree of glucose responsiveness in vitro, but a maximal response at subphysiologic glucose lev-Considerable effort has been exerted toward bioenels. Thus, they are now hoping to knock out hexokinase gineering artificial beta cells. Ideally, the patient's own in order to shift the range of glucose responsiveness cells could be modified to obviate the problem of graft (8, 36, 85) . rejection. Early attempts demonstrated that it was easy Another very attractive approach is to immortalize to modify human cells such as fibroblasts; however, rodent islets to produce cell lines that are glucose rethese cells will then produce proinsulin in an unregusponsive. Efrat and co-workers have produced a series lated fashion.
of such cell lines called βTC, by expressing a transform-Bioengineering an entire beta cell is exceedingly ing gene (i.e., simian virus 40 T-antigen) in beta cells of more complicated (119) . Insulin secretion by the beta transgenic mice via the insulin promoter/enhancer (19cell is a complicated process. In addition to the insulin 21,56). A similar approach has been used by Miyazaki gene, the regulatory system that turns on preproinsulin and co-workers, resulting in a cell line called MIN6 transcription and links its rate of transcription to blood (46) . Although tremendous progress has been made in sugar levels would have to be fully characterized and this field, additional problems that still need to be adinserted. Furthermore, insulin is synthesized as preproinsulin, which must be cleaved to proinsulin and then in-dressed include long-term stability in vivo, lower levels of insulin production, and secretion of rodent rather than PORCINE ISLETS: PROS AND CONS human insulin.
Porcine islets are currently considered by many to be Another interesting approach has been to transfect a the preferred choice for clinical islet xenotransplantation human hepatoma cell line (HEP G2) with both the insufor a variety of reasons (60, 61) . First, the amino acid lin gene and the GLUT-2 transporter, resulting in a cell sequences of porcine and human insulin are identical exline (HEP G2ins/g, also called Betacyte) with the ability cept for position 30 on the B-chain, where ALA replaces to synthesize, secrete, and store insulin; these cells are the human THR. Equally important, porcine diet and also glucose responsive, but, unfortunately, most of their physiology are relatively similar to those of humans. insulin production and secretion appears to be constitu-Other practical reasons for using porcine islets are that tive (113) . In vitro, stable expression of both the insulin the technology to harvest porcine islets already exists and GLUT-2 genes is dependent upon continued expo-(2,6,77,102,103) and the possibility that the remainder sure to the antimicrobial agents G418 and hygromycin of the donor animal could be processed for human con-B. However, when Betacytes are transplanted into imsumption, partially subsidizing the cost of procuring the munoincompetent mice in the absence of these agents, islets. gene expression diminishes, resulting in decreased insu-On the other hand, significant problems would have lin production and loss of regulated secretion (125).
to be addressed to allow wide-spread porcine islet xeno-Although some of the above-mentioned approaches transplantation. Although several excellent methods for might be possible at some time in the future, none are harvesting porcine islets have been reported (2,6,77, currently available for clinical trials. Furthermore, these 102,103), isolation of porcine islets is expensive and can approaches ignore the fact that the islet is not composed be problematic. Current costs (including reagents and of only beta cells; the other islet cell types (i.e., alpha, technical support) are estimated to be $6,000 per pandelta, and PP) play roles in regulation of beta cell funccreas (personal communication, Dr. Camillo Ricordi, 21/ tion and optimal coordination requires cell-cell contact 8/2000); however, some economy of scale could be ex- (53, 92) . This would clearly not be possible with artifipected. One critical problem has been the inability of cial beta cells. We suggest that, at least in the foreseeany of the various collagenase companies to produce able future, only a beta cell, preferably as part of an uniform lots of "islet collagenase" (i.e., an ill-defined islet, can "recognize" high and low blood sugar levels blend of about 30 different enzymes) (106). This marked and respond appropriately. However, another promising variability in collagenase lots has resulted in great diffiand very new approach, which may circumvent some of culty isolating human or porcine islets reproducibly; these issues, is the attempt to produce islets from panhowever, a new collagenase product, Liberase, has creatic stem cells (96) .
shown considerable promise to decrease the variability Although much progress has been made toward biobetween islet isolations (71) . engineering an artificial beta cell, the original goal of Several groups of investigators have suggested the avoiding graft rejection by modifying the patient's own use of neonatal (57, 97, 131) or fetal (29,74,112,114) pig cells has been lost in much of this research. Therefore, pancreas (sometimes called islet cell clusters or isletthese rodent-derived artificial beta cells would still have like cell clusters) as a potential donor source. The major to be protected from xenograft rejection. Because these advantages of fetal and neonatal pig islets are that these would be neoplastic cell lines with a potentially unlimcell clusters are more easily and reproducibly harvested ited ability to proliferate, they would probably have to and that they continue to proliferate after transplantabe encapsulated so that they could be easily removed tion. The major disadvantages are that they have relafrom the patient if necessary. Other problems are likely tively limited ability to proliferate, that they often generto result from the use of viral promoters because there ate a smaller percentage of beta cells than present in is evidence that they may not be suitable for mainteadult islets, that there is generally a long latency period nance of long-term, high-level expression in cell lines after transplantation (i.e., up to several months) prior to implanted in vivo. Another major problem is all insulininducing normoglycemia, and that multiple litters of feoma cell lines and genetically engineered artificial beta tuses or piglets would be required for a single human cells secrete only a fraction of the insulin secreted by transplant. A small number of diabetic patients have re-"real" beta cells. Finally, all of these approaches use ceived between 200,000 and 1,000,000 fetal pig islet cell mammalian cells, which have high oxygen requireclusters, derived from 39-100 donor fetuses (i.e., 4-8 ments. Therefore, it may also be necessary to genetically litters/transplant), with evidence of graft viability for up engineer these cell lines to tolerate the hypoxic condito several months in some recipients (29). tions often encountered within encapsulation devices Another formidable problem, common to all xenoge- (17) . In other words, many problems have yet to be solved.
neic donor sources, is the possibility of transmission of xenozoonoses. Zoonoses are diseases of animals that can transplants will not be inexpensive (73) . We believe that be transmitted to humans under natural conditions, while another, more cost-effective, approach will soon replace xenozoonoses are animal diseases transmitted via xenoporcine islets. transplantation. Because of occupational, dietary, and other exposure to pigs over thousands of years, there is PISCINE ISLETS: TILAPIA substantial medical literature documenting standard por-During the past several years, we have developed a cine zoonoses (40, 69, 161) . Many of these zoonotic unique animal model for islet xenotransplantation utilizagents are well characterized and easily identifiable using tilapia (Fig. 1) , a teleost fish, as islet donor (134, ing available diagnostic tests; these agents should not 151). The islet tissue in certain teleost fish, called principose a major problem for xenotransplantation as they pal islets or Brockmann bodies (named after a 19th cencan be excluded from the donor animal population. tury ichthyologist who described them in his doctoral However, there is little known about other potential xenodisseration), is anatomically distinct from their pancrezoonoses, and there is considerable public health conatic exocrine tissue and can be easily identified macrocern over the possibility of transmission of unknown scopically (22, 23, 162) . Expensive and fickle islet isolaagents from graft to recipient and then, potentially, from tion procedures, such as required when procuring islet the recipient to the general public (1,7,79,161). Particutissue from mammalian pancreases, are unnecessary. lar concern exists pertaining to the transmission of pig
The islets can be simply harvested by microdissection endogenous retroviruses (PERVs), C-type retroviruses (135,150) or enzymatically mass harvested (157) . Our present in cells of the domestic pig that are capable of laboratory and another have previously shown that tiinfection, replication, and serial transfer in a range of lapia islets transplanted into diabetic nude mice will prohuman cell lines (89) . Very recently, it has been shown duce long-term normoglycemia and mammalian-like that pig islets can produce PERVs that can infect human glucose tolerance profiles (82, 149) . cells in culture and that, after transplantation of porcine Many of our recent studies with this model have foislets into NOD/SCID mice, PERVs can be transcripcused on screening various immunosuppressive drugs tionally active and infectious across species (127) . and methods of graft immunomodulation as well as To minimize the risk of xenozoonoses, FDA stanstudying the mechanism of discordant cellular xenograft dards will require that all donor pigs be produced under rejection (9,14,87,141-145,154). Our results, to date, at least specific pathogen-free conditions (SPF) in dedisuggest that long-term survival of tilapia islet xenografts cated biomedical animal facilities meeting FDA and using temporary immunosuppression [(143), unpub-American Association for the Accreditation of Laboralished data], graft immunomodulation (i.e., low-tempertory Animal Care (AAALAC) standards (126) . SPF ature culture, hyperoxic culture, long-term culture, graft pigs, caesarian-derived and gnotobiotic at birth, have irradiation, or cryopreservation) prior to transplantation been commercially available to pig farmers from various (87,141,154), or transplantation into immunoprivileged laboratories approved by the National SPF Swine Acsites (9) is exceedingly unlikely. On the other hand, our crediting Agency since the late 1950s. These have been results suggest that long-term function of tilapia islet xeused as breeding stock to start clean herds, but, until nografts can be achieved with continuous high-dose imnow, there has little reason to try to maintain SPF condimunosuppression, but, thus far, only when administered tions throughout the live span of a herd (105) . Maintainat toxic or lethal levels (142). All of the above-mening SPF piggeries has thus far only been done on a small tioned studies suggest that tilapia islets are as immunoscale. Because multiple donor pigs will be required per genic as islets from other discordant donor species (34), islet recipient, the scale-up cost to transplant hundreds and, with the exception of encapsulation, we are not of thousands of diabetic patients will be immense (73) .
aware of any method of preventing discordant islet xe-Each housing facility will require a bank of operating nograft rejection. Although we are still trying to develop rooms meeting government, industry, and animal care better immunosuppressive regimens for safely preventregulatory standards for caesarian-rederivations to maining discordant xenograft rejection, it currently seems tain the SPF status of the herd and for performing donor likely that immunoseparation may prove to be the only pancreatectomies. The development of SPF piggeries is practical method to achieve safe discordant islet xenolikely to be a growth industry during the next few years transplantation. In our initial studies encapsulating tibecause government regulatory guidelines will specifilapia islets using a nonproprietary method (66,67,156, cally exclude the use of donor pigs from slaughterhouses 159,160), we were able to achieve uniform or near-uni-(26, 93, 126) .
form long-term function in streptozotocin-diabetic mice It is highly probable that porcine islets will be the (156,158) and have achieved similar results in rats first donor source for clinical islet xenotransplantation but, because of some of the problems listed above, these (159, 160) . Next, we plan to replicate these studies using spontaneously diabetic rodents and then eventually large on the well-documented fact that fish are severely glucose intolerant (43,80,88). However, fish islets are animal models.
Although our laboratory has published extensively on highly glucose responsive, both in vitro and in vivo (80, 138) . Glucose intolerance in tilapia, and probably the use of tilapia islets as a model for islet xenotransplantation and advocates exploring their possible clinical most fish, appears to be due to severe peripheral resistance to the glucostatic effects of insulin due to the ab-use, we were not the first to use fish islets in the treatment of either diabetic patients or experimental animals.
sence of an insulin-responsive GLUT-4 glucose transporter in piscine peripheral tissues (138,147). Tilapia The earliest use of BBs actually dates back to the discovery of insulin. J. J. R. Macleod, Banting and Best's islets appear to be at least as glucose responsive and efficient producers of insulin as rodent islets. In a previ-mentor at the University of Toronto, produced insulin from several piscine species and successfully treated di-ous study, we transplanted equal volumes of tilapia, rat, or mouse islets (i.e., 500 islet equivalents) under the re-abetic patients in Toronto in 1922 and 1923 (134) . During World War II, many German and Japanese diabetic nal capsules of streptozotocin-diabetic nude mice and followed them for 30 days. Mean nonfasting blood glu-patients were maintained on fish insulins (134) . In the early 1970s, Keith Reemtsma and Collin Weber origi-cose levels (±SEM) in recipients of tilapia, rat, and mouse islets were 77.8 ± 4.4, 77.0 ± 1.3, and 115 ± 4.5 nated the concept of fish islet xenotransplantation when they transplanted BBs from a variety of piscine species mg/dl, respectively. All three groups of recipient mice had glucose tolerance profiles with mean glucose disap-into STZ-diabetic rats (98, 129) . Although they had limited success because they utilized islet tissue from cold-pearance rates (K values) between 4.3 and 5.7. Based on our cell counts and on the observation that it takes about water species and because their studies predated the availability of athymic rodents (134), these two impor-2000 human or porcine islet equivalents to normalize diabetic nude mice, tilapia islets and rodent islets appear tant studies foreshadowed future studies. In the mid-tolate 1980s, Jurgen Schrezenmeir and Christian Laue to be at least several-fold more efficient than human or porcine islets (153). This finding is consistent with an-completed a series of important studies using BBs from a tropical fish, Osphronemus gorami; Schrezenmeir and other report suggesting that rodent islets produce roughly 3 times (basal) to 17 times (stimulated) as much Laue reasoned that islet tissue from cold-water species would not function optimally in homeothermic recipi-insulin per cell as human or porcine islets (15) . ents and then showed that gorami BBs could tolerate ISLET ENCAPSULATION, HYPOXIA, AND and function at mammalian body temperatures both in CYTOTOXIC CYTOKINES vitro and in streptozotocin-diabetic nude mice (68,109-Islet encapsulation prevents direct graft revasculariza-111). The history of piscine insulin and piscine islet tion after transplantation and oxygen must enter encaptransplantation has been reviewed in detail elsewhere sulation devices via diffusion. One problem that has (134) .
plagued investigators working with the various bioartifi-ISLET FUNCTION/METABOLISM cial pancreas technologies is that much of the initial islet volume is lost after encapsulation because of central ne-There is a widespread misconception that fish islets are not particularly glucose responsive, which is based crosis secondary to hypoxia. Central necrosis is particu-larly problematic because the insulin-producing beta BB insulin secretion. As with hypoxia, one approach to remedy this with mammalian islet cells is to attempt to cells comprise the central portion of each mammalian islet (128) . We believe that piscine islets may be ideal genetically engineer cells to be more resistant (17, 37) . Although we do not yet have any direct data on their for bioartificial pancreas applications because they are resistant to hypoxia. Fish are adapted to live in a rela-susceptibility to toxic mammalian cytokines, we do know that tilapia islets are exceedingly resistant to the beta tively hypoxic environment (i.e., water) (5,91,117) and tropical fish like tilapia tolerate even lower oxygen ten-cell toxin streptozotocin (137), a drug that induces diabetes in rodents and a number of other mammalian spe-sions because warm water holds less oxygen than cold water (132) . Because tilapia can live in stagnant water, cies by causing DNA strand breaks in beta cells. There is now substantial evidence that the diabetogenic effects we speculated that tilapia islets might tolerate lower oxygen tensions than mammalian islets. To test this hy-of streptozotocin are markedly potentiated by nitric oxide and by various cytokines that are also known to in-pothesis, we cultured tilapia and rat islets under severely hypoxic conditions and tested viability using the fluores-duce DNA strand breaks in beta cells (16, 50, 58, 146, 163) . It is, therefore, very reasonable to speculate cein diacetate/ethidium bromide method at intervals ranging from 2.5 h to 7 days. Under these conditions, rat that tilapia islets, which are resistant to streptozotocin, may be less susceptible to damage from some of the islets underwent near total necrosis and fragmentation in <24 h but tilapia islets were roughly 50% viable at 7 above-mentioned inflammatory mediators. days. Function was confirmed by culturing fish islets ISLET PROCUREMENT under severely hypoxic conditions (media, pO 2 = 27.8
Tilapia islets, relative to mammalian islets, are very mmHg) for 3 days and then transplanting them into diasimple and inexpensive to harvest and purify. The main betic nude mice; rat islets cultured under the same conreason for this relates to the anatomies of the teleost and ditions were entirely necrotic and no residual islet tissue mammalian pancreata. In mammals, the islet tissue is could be identified for transplantation. This study conscattered throughout the exocrine pancreas and comcluded that tilapia islets will survive and function at prises only about 1% of the total pancreas ( Fig. 2A ). In lower oxygen tensions than mammalian islets (152) . The many types of teleost fish, the endocrine and exocrine media oxygen tensions used in this study were similar tissues are segregated. In tilapia, the islet tissue exists as to those found within the centers of encapsulated islets multiple, anatomically discrete organoid structures called (108). Because fish islets tolerate hypoxia better than Brockmann bodies ( Fig. 2B ), which are embedded in mammalian islets and because hypoxia is probably the adipose tissue adjacent to the common bile duct while primary mechanism of graft attrition after encapsulation, much of the exocrine pancreas is scattered throughout it seems very likely that encapsulated fish islets would the liver (i.e., a hepatopancreas). Tilapia islets can be need to be replaced less frequently than encapsulated mass harvested simply by removing the islet regions mammalian islets and could even facilitate the use of ( Fig. 3A, B ), adipose and all, from multiple donor fish less oxygen-efficient capsule designs. Additionally, the and incubating these regions together in a shaker water topographical arrangement of the various endocrine cell bath at 37°C for 10-15 min in a collagenase solution. types within tilapia islets is such that central necrosis At the end of the incubation, the collagenase solution is would not preferentially lead to beta cell loss, as occurs diluted and the islets sediment to the bottom of the diwith mammalian islets. In tilapia islets, small clusters gestion tube to form a pellet while the adipocytes float of beta cells surrounded by non-beta cells are scattered to the top of the tube and form a layer of fat cells (157) . throughout each islet (155) .
Unlike harvesting human or porcine islets, special lots One serious drawback to the concept of using encapof exotic blends of collagenase and expensive Ficoll grasulation to protect islet xenografts is that cytokines and dients are not required. Our method simply uses stanother inflammatory mediators, which are small moledard type II collagenase (or type VII, unpublished obsercules, can freely diffuse into encapsulation devices. It is vation) and all lots that we have tested work equally well established that chronic exposure to IL-1 inhibits well. This method is described in detail elsewhere (157) . insulin secretion in mammalian islets and, combined with other cytokines, may be cytotoxic (75,94). High DONOR PRODUCTION COSTS local concentrations of other cytokines, especially in combinations, also have deleterious effects on cultured Tilapia (genus Oreochromis) are omnivorous freshwater fish that are native to Africa, the Middle East, islets (16, 94, 120, 139) . Because of the millions of years of phylogenetic disparity between humans and tilapia, it and India, but have now been introduced around the world as an aquaculture crop. There are a variety of ti-is quite plausible that human cytokines might have little effect on piscine islets. Therefore, we plan to examine lapia species; most are extremely versatile and tolerate marked variation in ambient water temperature and oxy-the effects of recombinant human cytokines on tilapia Worldwide production of tilapia as a food fish in 1996 exceeded 1.6 billion pounds and has been increasing fed by hot springs where the diurnal temperature and oxygen levels fluctuate from 42°C with oxygen super-14.2% annually since 1984; tilapia production currently represents roughly 5% of farmed finfish (124) . saturation (due to cyanobacterial photosynthesis) during the day to 25°C and near anoxia (due to cyanobacterial Tilapia can be very inexpensively produced in aquaculture. North American production exceeded 15.5 mil-respiration) at night. This lake is believed to provide the harshest conditions inhabited by any species of fish; lion pounds in 1997 (124) . Almost all of the North American tilapia were produced in outdoor fish farms in other than cyanobacteria, it is inhabited only by tilapia and one small crustacean species (133) .
the southern and western United States. These farms would not begin to approach FDA or AAALAC stan-Our donor species is Oreochromis niloticus, which breed easily and grow rapidly, attaining a maximum dards. However, we have seen a large indoor production facility for tilapia with an energy efficient recirculation source of islet tissue for treating IDDM, the donors would also generate a high-quality, inexpensive protein system and biofilters, which we believe currently meets AAALAC standards and could be modified to meet source and potentially improve the diet (and health) of the general population. FDA standards. This facility produces and markets live tilapia as a food fish in Canada at a profit based on the One of the major advantages of tilapia as a potential islet donor, compared with pigs, is production costs. market value of live tilapia. This suggests to us that a donor tilapia facility could be inexpensively operated.
Large numbers of porcine or piscine donors would be required to implement widespread clinical islet xeno-Furthermore, portions of the residual tilapia donor carcasses could be processed for human consumption and transplantation (73) . Tilapia, in general, are about 2.5fold more efficient at converting food into body mass, other portions processed as animal feed or fertilizer-all of which could greatly subsidize donor production costs.
produce less waste products per kg/body mass, have shorter generation times (i.e., conception to sexual matu-Therefore, in addition to providing an inexpensive rity, 6 months vs. 12 months), larger "litter" sizes Streptococcus iniae, a piscine bacterium that has caused disease outbreaks in populations of tilapia in Japan (55) (100s-1000s vs. <10), and minisucle space requirements relative to pigs. For instance, a thousand donor-sized ti-and Texas (90) , made the news by infecting several people cleaning infected fish; although the septicemia and lapia could be housed in about the same amount of floor space as one donor-sized pig (73) . Furthermore, female localized cellulitis were easily cured with antibiotics, this appears to be a rare example of a fish bacterium that tilapia produce eggs approximately every 2 weeks and could, at least theoretically, produce 26 "litters"/year is infective in humans (130) and, therefore, would be a specific pathogen that would have to be excluded from while a sow can produce only two litters/year. Although too convoluted to explain here, we estimate that the total colonies of tilapia used for islet procurement. Although our tilapia sources have repeatedly tested negative for islet production costs of pig vs. tilapia islets (including islet isolation costs but excluding the market value of this organism, it is currently unknown whether the organism is rare or widespread in populations of tilapia. the remainder of the donor carcasses as food) per clinical islet transplant favor tilapia by at least a 100:1 ratio.
Regardless, pathologic strains of S. iniae are likely to be rare as only a handful of epizootic outbreaks in aquacul-Tilapia are an extremely hearty and competitive species. Although not native to North America, tilapia that ture systems have been identifed worldwide and only one small series of cases of zoonotic infection has been have escaped from fish farms have established themselves in freshwater ponds and lakes throughout the documented so far, even though tilapia aquaculture worldwide exceeds 1.6 billion pounds annually. Regard-southern United States to such an extent that they are considered a threat to the ecosystem in some locations. less, as a bacterium, it should be relatively easy to exclude from production colonies of donor tilapia. In gen-Furthermore, many strains of tilapia also tolerate brackish water and even saltwater. Because tilapia are so eral, disease transmission from mother to offspring (i.e., vertical transmission), which can occur in utero, at de-hearty and because of environmental concerns when dealing with genetically altered or transgenic animal livery, or when nursing in mammalians, appears to be much less of a problem with fish because the eggs are species (see below), we feel that tilapia production facilities for future islet donors are more appropriately lo-fertilized and develop externally. In other words, fish are automatically caesarian-rederived at each generation cated in northern climates where fish could not survive outside of the production facility. and disease transmission is mostly based upon eggs or fry being introduced into a contaminated environment.
PISCINE ZOONOSES AND XENOZOONOSES
Transmission can be further reduced by performing in vitro fertilizations, as is standard in our tilapia facility. From the perspective of transmitting xenozoonotic diseases, it is reasonable to speculate that tilapia islets Because eggs have a protective shell, the surface can be chemically treated to prevent transmission of organisms. are likely to be safer than islets from mammalian sources. Many believe that the probability of transmit-Specific treatments with antibacterial, antifungal, and/or antiviral activities are approved by the FDA for disin-ting xenozoonotic diseases decreases with increasing phylogenetic disparity between donor and recipient. For fecting eggs of food fish (121) . With appropriate aquaculture technique and careful attention to detail (32), it instance, several important simian viruses are known to be highly infectious in humans (2,7,79) and there is evi-should be possible to maintain SPF tilapia facilities. On a small scale, several investigators have even succeeded dence that the current AIDS epidemic had a simian origin; therefore, most infectious disease experts feel that in maintaining germ-free fish (72) . Currently, there are no known fish viruses that are primates are not suitable donors for xenotransplantation. Although the phylogenetic disparity between pigs and infective in man (84,140). Retroviruses have been described in some fish species and their occurrence humans exceeds that of primates and humans, the disparity between teleost fish and humans is hundreds of appears to be sporadic (18, 25, 33, 38, 107, 122) . While screening a number of teleost species, we identified a millions of years greater.
Because the human has thousands of years of occupa-retroviral sequence similar to the Moloney murine leukemia virus in salmonids (i.e., trout and salmon), but not tional and dietary exposure to fish, there is considerable literature on piscine zoonotic diseases (84,140). The vast in tilapia (122) . Although no tilapia retroviruses have been identified to date, their existence cannot be ex-majority of piscine zoonoses are recycled human bacterial diseases, which are acquired in places where sanita-cluded. tion is poor and food fish are exposed to human sewage.
CRYOPRESERVATION AND CULTURE Most of the zoonoses seen in tilapia probably fit into this group (104) . This group of zoonoses is entirely pre-Islets are an end-stage, fully differentiated tissue that does not proliferate in tissue culture. However, mamma-ventable by improving sanitation and water quality. Other types of zoonoses are exceedingly rare. Recently, lian islets can be maintained in culture temporarily. We have maintained tilapia islets in culture under a variety TRANSGENIC FISH of conditions (141) for up to 1 month. Morsiani et al. In recent years, one approach to solving some of the (82) have exceeded this and cultured tilapia islets for up problems in the aquaculture industry has been to proto 150 days without evidence of degranulation. duce transgenic fish that will grow rapidly and will tol-We recently demonstrated that tilapia islets can be erate adverse environments (24, 27, 30, 35, 47, 136) . Most cryopreserved using a standard mammalian islet protoof these efforts have been directed at insertion of growth col, thawed, and successfully transplanted into diabetic hormone transgenes. Another approach has been to innude mice (87). Cryopreservation resulted in some tissert antifreeze genes from species that tolerate very cold sue loss, which had to be compensated for by transplantwaters, such as winter flounder, into other species so ing additional islet volume. We are attempting to optithat they will not only survive, but actually thrive in mize the protocol for tilapia islets through collaborative colder water. This approach permits aquaculture in more efforts (62).
northerly regions and allows aquaculture stocks to grow year-round, rather than just during the summer growth INSULIN STRUCTURE season.
Tilapia islets meet most or all of Dionne et al.'s crite-
Production of transgenic fish is not yet as straightforria (15) for an ideal insulin-producing tissue for encapward or routine of a process as production of transgenic sulation. However, there is one major problem; tilapia mice for several reasons (30, 136) . The rate of successful islets produce tilapia insulin (see Fig. 4 ) and tilapia insutransfer and integration of DNA in a good transgenic lin differs from human insulin by 17 amino acids: 9 in mouse facility is about 25% but is much lower for fish. the A-chain and 8 in the B-chain (86) . Although human Microinjection is more efficient with mouse eggs bediabetics have at various times in the past been maincause the eggs are small, the pronuclei are visible, and tained long term on teleost fish insulins without any obthe eggs are not surrounded by hard shells. On the other vious deleterious effect (134) , these structural differhand, fish eggs are several thousand-fold larger than ences create two potential problems that might prevent mouse eggs. While the nuclear/cytoplasmic ratio in a clinical islet xenotransplantation using tilapia islets.
mouse egg is 1:20, it may be up to 1:100,000 in a fish First, some patients would undoubtedly develop antibodegg (mostly because of the large amount of yolk). Beies to tilapia insulin, resulting in insulin resistance. Seccause of this greater volume, the pronuclei in fish eggs ond, most teleost insulins exhibit only one third to one may be difficult to localize. Furthermore, the rapid onset half of the biological potency of human insulin (138).
of cleavage and the hardening of the chorion following Tilapia insulin, by virtue of having GLU rather than fertilization create additional problems. If injected after GLN at position 5 in its A-chain, might interact with the the one-cell stage, the resulting fish are mosaic for the human insulin receptor less favorably than even other transgene. Finally, egg morphology can be vastly differteleost insulins (86) . Because of this relative inactivity ent between species of fish (24) . in man, many more islets would have to be transplanted to achieve normoglycemia.
The probability of success when microinjecting fish eggs is largely dependent upon the investigator's level junction after threonine using recombinant protein produced in E. coli transfected with the +THR construct. of practice. Embryonic survival following microinjection is normally 80-90% of uninjected controls. The Currently, we are producing transgenic tilapia using the −THR construct. The structure of the insulin pro-insertion rates are extremely variable and depend on species and a myriad of other factors. However, the rela-duced by these fish should be identical to human insulin except that it will be missing the terminal THR in the tively high rate of mosaicism and the low transgenic levels can be compensated for by injecting large numbers B-chain. Based upon the known activity of porcine insulin in humans (i.e., which differs from human insulin of eggs. To diminish the probability of mosaicism, the eggs can be cooled, which slows the initial cell division only at the terminal aa in the B-chain), this form of humanized insulin should be functional and nonimmuno- (95) . A skilled investigator can achieve rates of injection of between 50 and 1000 eggs/h depending on the types genic in humans. However, if our studies show that it is possible to produce a humanized tilapia insulin that is of eggs, the logistical support, the accuracy of injection, and "egg quality" (30). Unlike mice, which produce up identical to human insulin using the +THR construct, we will begin production of these fish. Because we have to 10-15 eggs at a time, fish may produce many thousands of eggs at once. Tilapia are particularly prolific not altered the C-A junction, processing of the A-chain should not be altered in either type of transgenic fish. and are, in many ways, ideal for transgenic studies. Unlike many other teleost fish species that spawn once a Therefore, based on the structure of the humanized tilapia insulin genes that we are microinjecting, "human-year, female tilapia are ready to spawn every 2 weeks. Tilapia grow quickly and become sexually mature in ized" tilapia insulin should either be identical to human insulin or will lack the terminal THR on the B-chain. 5-6 months.
We are producing transgenic fish through the labor-PRODUCTION OF TRANSGENIC TALPIA WITH intensive method of injecting thousands of fertilized ti-A "HUMANIZED" TILAPIA INSULIN GENE lapia eggs with the humanized insulin gene. Once reintroduced into fertilized tilapia ova by microinjection at Using an in vitro polymerase chain reaction (PCR) cloning strategy (Takara Shuzo Co. Ltd) and nested de-the single-cell stage, the hybrid tilapia/human insulin gene should contain enough tilapia sequences (i.e., ap-generate primers based on conserved amino acids from human and several teleost fish insulins, we cloned the proximately 99%) so that homologous recombination will occur in a minuscule percentage of transgenic fish. entire tilapia insulin gene, including approximately 1.5 kb of DNA at both ends of the gene. The complete cod-
We have now produced small numbers of transgenic tilapia and are currently producing more. We are also ing regions, including the leader sequence, B-chain, Cpeptide, and A-chain, have been sequenced (76). There screening these for homologous recombination. Once a homologous recombinant founder has been identified, is 100% identity between the deduced amino acid sequence and the protein sequence obtained using amino we will breed for homozygosity and then institute a breeding program to develop, in collaboration with ex-acid sequencing of purified tilapia insulin (86) .
Using site-directed mutagenesis and linker substitu-perts in tilapia genetics and aquaculture, genetically stable production strains of tilapia with islets that produce tions, we have "humanized" the tilapia insulin gene so that it contains exons that code for human insulin while only humanized insulin. If we are unable to achieve homologous recombination, it is likely that our transgenic still maintaining all of the tilapia regulatory (noncoding) sequences (148) . The substituted codons were devised fish will produce both humanized insulin and tilapia insulin simultaneously. Depending upon the relative ratio so that they code for the human insulin chains but still use tilapia preference codons in order to get proper pro-of these, such fish might still prove to be excellent islet donors. tein expression. We did not alter the tilapia preinsulin leader nor the C-chain. This construct maintains all the At the current time, we have produced over a dozen founder transgenic tilapia that have consistently screened similar recognition sites for the endopeptidases and, therefore, transgenic fish should technically process this positive for incorporation of our −THR humanized tilapia insulin gene construct. Because of the relatively modified protein as the native insulin. We have constructed two versions of the humanized tilapia gene. The small blood volumes in fish and the potential value of these founders, we have not done any direct testing of first construct lacks the terminal threonine (−THR) that is present on the human insulin B-chain (i.e., like native them because drawing large volumes of blood for testing could be lethal. However, when bred to nontransgenic tilapia insulin); this will guarantee proper cleavage of the B-C chain. Our second construct contains the termi-tilapia, the transgene has been transmitted in up to 25% of the F1 offspring. Preliminary testing on F1 transgenic nal B-chain threonine (+THR) that is present in the human insulin B-chain. We are now testing whether the tilapia has been very promising. Using a commercial radioimmunoassay (Phadeseph Insulin RIA, Pharmacia & tilapia endopeptidase will cleave this modified B-C Upjohn, Uppsala, Sweden), which consistently does not their development, allowing donor-derived blastomeres to populate their germ-lines (48). Although these irradia-cross-react with tilapia insulin, we have found high serum insulin levels in nonfasted transgenic tilapia (i.e., tion experiments were performed with donor blastomeres rather than ES cells, this method should also be several-fold higher than normal levels for nonfasted normal human subjects); as expected, insulin could not be applicable to ES cells.
To date, no one has yet tried to develop tilapia ES detected by the RIA in the serum of control, nontransgenic tilapia that were run simultaneously. Cur-cells or chimeras. To learn this methodology and establish it in our laboratory, one of us visited a top zebrafish rently, we are attempting to develop an assay that is specific for tilapia insulin so that we can determine the laboratory. Unfortunately, we quickly found that zebrafish methods are not directly adaptable to tilapia without relative ratio of humanized insulin to tilapia insulin in the serum of these fish. Thus far, the transgenic fish major modification at almost every step. For instance, the chorion surrounding the developing blastula is much appear healthy and we have not noted any difference in the serum glucose levels between transgenic and non-thicker in tilapia embryos and is resistant to digestion with pronase (i.e., the method of freeing the blastulas in transgenic tilapia, suggesting that insulin production and secretion is regulated (preliminary unpublished data). zebrafish). In zebrafish, the blastulas are harvested at 3 h after fertilization (roughly the 1000-cell stage); tilapia Preliminary histological examination of transgenic and nontransgenic fish islets has also been interesting.
are not even approaching a blastula stage at 3 h. Therefore, we have had to study embryonic development in By immunoperoxidase staining using any of three antibodies to human insulin that do not cross-react with ti-tilapia to solve some of these problems as they arise (81) . For instance, we have found that the 1000-cell lapia insulin, intense immunopositivity can be identified in the beta cells in transgenic fish but not in the beta stage occurs at roughly 10 h postfertilization in tilapia.
We have also discovered the location of the "hatching cells of control fish. Staining for somatostatin and glucagon appear similar in control and transgenic fish islets glands" in developing tilapia embryos (tilapia embryos use a hatching enzyme to break free of their eggs at and no changes in islet cell topography have been noted (preliminary unpublished data).
the time of hatching). The hatching glands had never previously been described in tilapia embryos and we ANOTHER APPROACH have used this knowledge to make a hatching solution that we have successfully used to dechorionate the de-Ideally, we would like to achieve homologous recombination rather than random gene inserts. In mice, em-veloping embryos so that we can get at the blastulas without destroying them. We believe that an ES cell ap-bryonic stem (ES) cell technology has been used extensively to produce targeted gene mutations and gene proach should be possible with tilapia, but it will take time to work out the details. Using the same tissue cul-knockouts in vitro (28, 49) . Transfected ES cells can then be injected into developing blastulas to generate chime-ture conditions and growth factors as used for zebrafish and medaka, we will attempt to develop ES cell lines ras, including germ-line chimeras, and these germ-line chimeras can be used to produce homozygous knockout from tilapia. If successful, these ES cells will be transfected with the humanized tilapia insulin gene. Transfec-mice. This approach should also be feasible in tilapia. It is now possible to grow zebrafish and Japanese medaka ted ES cells would then be place into newly developing tilapia blastocysts. We plan to use ES cells from our blastula cells in tissue culture and block their differentiation resulting in "ES-like" cells (39, 118, 123) . Others standard gray tilapia and developing blastulas from red tilapia (78) and use color to help us screen for chime-have successfully injected dispersed blastomeres from genetically pigmented zebrafish into developing blastu-rism (i.e., gray and red fish). We will then screen chimeric fish to determine if sperm or eggs have the altered las of albino zebrafish, resulting in somatic chimeras and rare germ-line chimeras (70) . Recently, stable medaka gene, breed positive fish to homozygousity, and then test for regulatable humanized insulin production. The ES ES cell lines were used to produce somatic chimeras; DNA transfection was also possible in these fish ES cells offer several advantages. Millions of cells can be transfected in vitro. Selectable markers offer a rapid lines. However, the ES cells did not repopulate the gametes in these chimeras (i.e., germ-line transmission) screening for cells that take up the DNA and also for rare homologous recombination events. Although the ES (39) . Like in zebrafish, only rare germ-line chimeras have been produced in medaka by injecting blastomeres cell technology, the transfection of the ES cells, and the production of germ-line chimeras are all new technolo-(42). However, very recently, it has been reported that moderate gamma-irradiation of recipient medaka em-gies that will need to be developed specifically for tilapia, we believe that this approach will eventually be bryos, followed by transplantation of dispersed blastomeres, achieves germ-line transmission in over 50% of successful as most of these technologies either exist or appear imminent in, at least, zebrafish and medaka. Very the resulting fish, probably secondary to a slowing of recent evidence suggests that these technologies can also II gene, which is either not present or not expressed in mammals (86) . Although the biological effects of SST-be applied to larger commercially important fish species (3). Even the last big hurdle (i.e., homologous recombi-28 in mammalian systems are currently unknown and would need to be investigated, this may not be a chronic nation) has now been achieved with zebrafish cells, albeit not yet with practical application (31). problem as we have preliminary evidence that tilapia SST-28 cells decrease in number and SST-14 cells be-POTENTIAL PROBLEMS come relatively more numerous over time after transplantation under the renal capsules of streptozotozin-dia-A question might also be raised whether human insulin might be toxic in tilapia or whether transgenic fish betic nude mice (unpublished observation); we suspect that the SST-28 cells may undergo apoptosis due to the producing mostly or exclusively human insulin would be viable. As mentioned earlier, tilapia insulin differs absence of appropriate trophic factors or feedback in an mammalian environment. from human insulin by nine amino acids in the A-chain and eight amino acids in the B-chain (Fig. 4) . Most tel-It currently seems unlikely that tilapia C-peptide, which is markedly different from human C-peptide, eost fish insulins exhibit one third to one half the biological potency of human insulin (86); alternatively, human would have any detrimental effect on human recipients. Evidence suggests that C-peptide, although present at insulin has a similar level of activity in fish. Because human diabetics have been maintained long term on the genomic level, may be catabolized intracellularly at the time of cleavage and, therefore, does not circulate in teleost insulin without any obvious deleterious effect (134) , it seems likely that transgenic tilapia would toler-teleosts. Thus far, no one has been able to isolate Cpeptide from any fish with Brockmann body-type islets ate human insulin. This premise is strongly supported by both our preliminary data with transgenic fish producing (10,11). If this proves to be correct, the absence of tilapia C-peptide might be fortuitous because it obviously humanized insulin and a recent study in which fish with total pancreatectomies were maintained with bovine in-could not circulate and precipitate antigen-antibody immune complexes in the recipient. On the other hand, its sulin (51). Nevertheless, it is possible that growth characteristics of the fish might be altered because of the absence would delete the standard method diabetologists use to measure endogenous insulin secretion after islet substituted amino acids in the humanized insulin and because of insulin's very potent action as a growth fac-transplantation. Obviously, all tilapia islet peptides would have to be studied further. tor in fish (52, 54) . However, this effect has not been apparent in our transgenic fish produced thus far. Inter-Mean fasting (>48 h) and nonfasting plasma glucose levels (±SEM) in tilapia are 75.4 ± 3.0 (n = 140) and estingly, our very preliminary data measuring humanized insulin in the serum of our F1 transgenic tilapia 91.9 ± 3.3 mg/dl (n = 202); equivalent values for humans are 63 and 90 mg/dl, respectively (138). Although suggest that serum insulin levels in nonfasted fish are several-fold higher than in nonfasted human subjects.
the average set-point for normoglycemia in tilapia appears to be within human norms, there is probably more We speculate that these higher levels may be due to the two-or threefold decreased biological potency of human variability than would be ideal. If the set-point for glycemia in transgenic tilapia proved to be too low, recipients insulin in fish rather than due to unregulated insulin secretion, as we have not seen significant differences in could experience hypoglycemia after transplantation. This is a potentially serious complication that could be plasma glucose levels between transgenic tilapia and control tilapia (unpublished preliminary data).
avoided by breeding parents selected for possessing higher set-points. Even if glucose-stimulated insulin se-Before clinical islet transplantation could be seriously considered, the control of insulin secretion by tilapia and cretion by the transgenic fish islets proved to be slightly suboptimal, they still might prove exceedingly useful for transgenic tilapia islets would have to be clearly understood. In particular, the mechanism of insulin release, bioartificial pancreases. It would be very plausible to load a patient with a large number of fish islets and a its feedback controls, its interplay with other pancreatic hormones, and the relative potency of other insulin se-much smaller number of human or porcine islets. Conceivably, the fish islets could provide the bulk of the cretogogues would have to be fully characterized. We will also need to examine whether several other peptides insulin production and the human islets could "fine tune" the insulin response just as short-acting and long-produced by tilapia islets would be biologically active, and potentially harmful, in humans. For instance, tilapia acting insulins are now mixed to optimize insulin therapy in diabetic patients. islets differ from mammalian islets in that they contain two types of delta cells: one that produces somatostatin-HOW MANY FISH ISLETS? 14 (i.e., a 14-amino acid SST identical to that produced by mammalian delta cells) and one that produces SST-One question that we have sometimes encountered is whether it would really be feasible to harvest enough 28, a "large" SST derived from the preprosomatostatin fish islets to transplant diabetic patients. A standard matic islet isolation procedures for procurement. Islets from these transgenic fish, once fully tested and charac-method used to estimate islet volume is to calculate islet equivalents (IEQ) (101) . It is estimated that about terized, could be harvested, encapsulated, and transplanted into diabetic patients. 20,000 IEQ/kg of recipient body weight would be required for successful clinical islet transplantation using using transgenic tilapia as donors should be 50-70% less, because teleost fish insulins are only 30-50% ac-REFERENCES tive in humans. Based on the known structure of tilapia 1. Allan, J. S. Xenotransplantation at a crossroads: Preveninsulin, it should be less active than the average teleost tion versus progress. Nat. Med. 2: 18-21; 1996. insulin because of the substitution of GLU in position 5 2. Basta, G.; Falorni, A.; Osticioli, L.; Brunetti, P.; Clalfiof the A-chain (86) . Assuming that tilapia insulin has ore, R. Method for mass retrieval, morphologic, and functional characterization of adult porcine islets of 30% activity in humans and that humanized tilapia insu-Langerhans: A potential nonhuman pancreatic tissue relin has 100% activity in humans, we estimate that about source for xenotransplantation in insulin-dependent dia-210 donor transgenic tilapia would be adequate. Using betes mellitus. J. Invest. Med. 43:555-566; 1995. our mass harvesting method (157) , this volume of tilapia
